STOCK TITAN
  1. Home
  2. Sec-filings
  3. AEON
  4. [Form 4] AEON Biopharma, Inc. Insider Trading Activity

Director Carter granted 222,684 RSUs at AEON Biopharma (AEON)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Carter Eric G reported acquisition or exercise transactions in this Form 4 filing.

AEON Biopharma director Eric G. Carter received an equity grant of 222,684 restricted stock units (RSUs) of Class A Common Stock. The award was granted on June 17, 2026 and carries no purchase price. The RSUs vest in full on the earlier of one year after the grant date or the 2027 annual stockholder meeting, subject to his continued service. Following this grant, Carter holds 258,705 shares directly.

Positive

  • None.

Negative

  • None.
Insider Carter Eric G
Role null
Type Security Shares Price Value
Grant/Award Class A Common Stock 222,684 $0.00 --
Holdings After Transaction: Class A Common Stock — 258,705 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 222,684 RSUs Award of restricted stock units on June 17, 2026
Grant price per share $0.0000 per share Compensation-related RSU grant with no cash cost
Post-grant holdings 258,705 shares Total Class A Common Stock held directly after transaction
Grant date June 17, 2026 RSUs granted to director Eric G. Carter
restricted stock units ("RSUs") financial
"Represents an award of restricted stock units ("RSUs") granted on June 17, 2026"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vest in full financial
"The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary"
annual meeting of the Company's stockholders financial
"the date of the 2027 annual meeting of the Company's stockholders"
continued service financial
"subject to continued service through the applicable vesting date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Carter Eric G
(Last)(First)(Middle)
C/O AEON BIOPHARMA, INC.
5 PARK PLAZA, SUITE 1750
(Street)
IRVINE CALIFORNIA 92614
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
AEON Biopharma, Inc. [ AEON ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock(1)06/17/2026A222,684A$0(1)258,705D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.
/s/ Alexander Wilson, as Attorney-in-Fact, for Eric G. Carter06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did AEON Biopharma (AEON) disclose in this Form 4 filing?

AEON Biopharma disclosed that director Eric G. Carter received a grant of 222,684 restricted stock units of Class A Common Stock. These RSUs were awarded at no cost and are subject to a time-based vesting schedule tied to service and the 2027 annual meeting.

How many AEON Biopharma shares does Eric G. Carter hold after this grant?

After the RSU grant, Eric G. Carter is reported to hold 258,705 shares of AEON Biopharma Class A Common Stock directly. This total reflects the addition of 222,684 restricted stock units awarded on June 17, 2026 under the company’s director compensation structure.

When do Eric G. Carter’s AEON Biopharma RSUs vest?

The RSUs vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the date of AEON Biopharma’s 2027 annual stockholders’ meeting. Vesting requires Carter’s continued service with the company through the applicable vesting date.

What type of transaction is reported for AEON Biopharma director Eric G. Carter?

The filing reports a grant or award acquisition transaction, coded “A” for 222,684 RSUs of Class A Common Stock. This is a compensation-related equity grant, not an open-market purchase or sale, and was received at a price of $0.0000 per share.

Does Eric G. Carter pay anything for the AEON Biopharma RSU grant?

No cash payment is required for this RSU grant; the reported price per share is $0.0000. The award represents stock-based compensation that vests over time, conditioned on Carter’s continued service and the timing of AEON Biopharma’s 2027 annual stockholders’ meeting.